drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody; EGFR inhibitor)
drug_description
Humanized IgG1 anti-EGFR (HER1) monoclonal antibody that blocks ligand binding, inhibits downstream RAS/RAF/MEK/ERK and PI3K/AKT signaling, enhances radiosensitivity, and can mediate ADCC via Fcγ receptors on NK cells.
nci_thesaurus_concept_id
C2733
nci_thesaurus_preferred_term
Nimotuzumab
nci_thesaurus_definition
A humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Nimotuzumab binds to and inhibits EGFR, resulting in growth inhibition of tumor cells that overexpress EGFR. This agent may act synergistically with radiation therapy.
drug_mesh_term
Nimotuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody against EGFR (HER1) that binds the receptor’s extracellular domain to block ligand binding and activation, suppressing downstream RAS/RAF/MEK/ERK and PI3K/AKT signaling to inhibit tumor cell proliferation and survival; also enhances radiosensitivity and can mediate ADCC via Fcγ receptor–bearing effector cells (e.g., NK cells).
drug_name
Nimotuzumab
nct_id_drug_ref
NCT06422156